Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
Mi Q Wave
Interventions
DEVICE

Turbox CRP kit

Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.

DRUG

rosuvastatin 20 mg,

The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects

DRUG

atorvastatin 40 mg

The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects

Trial Locations (1)

Unknown

Rawalpindi Medical University, Rawalpindi

All Listed Sponsors
lead

Rawalpindi Medical College

OTHER